Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:CNTB NASDAQ:CRVO NASDAQ:IMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.10+0.2%$6.08$4.50▼$11.54$132.60M2.3841,715 shs11,741 shsCNTBConnect Biopharma$2.36+1.3%$2.74$0.70▼$3.82$131.70M-0.21231,738 shs95,044 shsCRVOCervoMed$3.95+3.9%$4.03$3.51▼$13.13$35.18M-0.6339,662 shs60,088 shsIMDXOncocyte$5.01+1.0%$4.21$2.33▼$8.51$160.15M1.63491,854 shs422,184 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-4.55%+2.01%-12.50%+19.41%-18.69%CNTBConnect Biopharma-6.05%-5.67%-17.38%-4.12%+191.25%CRVOCervoMed-1.91%+2.98%-1.04%-28.44%-57.06%IMDXOncocyte-1.39%+23.69%+54.52%-32.24%+495,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.10+0.2%$6.08$4.50▼$11.54$132.60M2.3841,715 shs11,741 shsCNTBConnect Biopharma$2.36+1.3%$2.74$0.70▼$3.82$131.70M-0.21231,738 shs95,044 shsCRVOCervoMed$3.95+3.9%$4.03$3.51▼$13.13$35.18M-0.6339,662 shs60,088 shsIMDXOncocyte$5.01+1.0%$4.21$2.33▼$8.51$160.15M1.63491,854 shs422,184 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-4.55%+2.01%-12.50%+19.41%-18.69%CNTBConnect Biopharma-6.05%-5.67%-17.38%-4.12%+191.25%CRVOCervoMed-1.91%+2.98%-1.04%-28.44%-57.06%IMDXOncocyte-1.39%+23.69%+54.52%-32.24%+495,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$16.00162.30% UpsideCNTBConnect Biopharma 2.80Moderate Buy$8.67267.23% UpsideCRVOCervoMed 2.63Moderate Buy$23.00482.28% UpsideIMDXOncocyte 2.00Hold$12.00139.52% UpsideCurrent Analyst Ratings BreakdownLatest CRVO, CNTB, ACOG, and IMDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026CNTBConnect Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/27/2026ACOGAlpha Cognition HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/23/2026CRVOCervoMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/22/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.004/20/2026CRVOCervoMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ACOGAlpha Cognition Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.004/8/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.003/31/2026CNTBConnect Biopharma BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/27/2026IMDXOncocyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026CRVOCervoMed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $11.003/18/2026CRVOCervoMed Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $21.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha Cognition$10.22M12.99N/AN/A$2.88 per share2.12CNTBConnect Biopharma$60K2,223.12N/AN/A$0.75 per share3.15CRVOCervoMed$4.01M9.12N/AN/A$1.97 per share2.01IMDXOncocyte$4.06M39.89N/AN/A($1.10) per share-4.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$20.67M-$1.16N/AN/AN/A-202.23%-55.71%-43.78%5/14/2026 (Confirmed)CNTBConnect Biopharma-$55.48M-$1.00N/AN/AN/AN/A-88.21%-74.26%5/21/2026 (Estimated)CRVOCervoMed-$26.97M-$2.98N/AN/AN/A-672.80%-96.04%-82.88%5/11/2026 (Estimated)IMDXOncocyte-$50.22M-$1.62N/AN/AN/A-1,238.52%N/A-79.78%N/ALatest CRVO, CNTB, ACOG, and IMDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026CNTBConnect Biopharma-$0.29N/AN/AN/AN/AN/A5/14/2026Q1 2026ACOGAlpha Cognition-$0.41N/AN/AN/A$3.42 millionN/A5/11/2026Q1 2026CRVOCervoMed-$0.7875N/AN/AN/A$0.07 millionN/A3/31/2026Q4 2025CNTBConnect Biopharma-$0.30-$0.27+$0.03-$0.27$0.00 million($0.05) million3/26/2026Q4 2025ACOGAlpha Cognition-$0.27-$0.30-$0.03-$0.30$4.41 million$2.60 million3/26/2026Q4 2025IMDXOncocyteN/A-$0.27N/A-$0.72N/A$1.14 million3/13/2026Q4 2025CRVOCervoMed-$0.79-$0.88-$0.09-$0.88$0.84 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AIMDXOncocyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A8.658.09CNTBConnect Biopharma0.013.743.74CRVOCervoMedN/A4.914.91IMDXOncocyteN/A1.271.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/ACNTBConnect Biopharma58.72%CRVOCervoMed25.15%IMDXOncocyte55.35%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%CNTBConnect Biopharma22.60%CRVOCervoMed35.40%IMDXOncocyte2.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A21.77 million18.73 millionN/ACNTBConnect Biopharma11056.52 million43.75 millionOptionableCRVOCervoMed49.26 million5.98 millionNot OptionableIMDXOncocyte12032.29 million31.63 millionN/ACRVO, CNTB, ACOG, and IMDX HeadlinesRecent News About These CompaniesiMDx to Release First Quarter 2026 Results on May 13, 2026May 6 at 4:05 PM | globenewswire.comInsider Buying: Oncocyte (NASDAQ:IMDX) Major Shareholder Acquires 38,880 Shares of StockApril 28, 2026 | insidertrades.comOncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Purchases 38,880 SharesApril 27, 2026 | marketbeat.comBroadwood Partners, L.P. Buys 250,923 Shares of Oncocyte (NASDAQ:IMDX) StockApril 27, 2026 | marketbeat.comOncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Acquires 280,381 SharesApril 27, 2026 | marketbeat.comBroadwood Partners, L.P. Purchases 40,114 Shares of Oncocyte (NASDAQ:IMDX) StockApril 21, 2026 | insidertrades.comOncocyte (NASDAQ:IMDX) Major Shareholder Acquires $143,206.98 in StockApril 20, 2026 | marketbeat.comOncocyte (NASDAQ:IMDX) Major Shareholder Acquires $157,877.20 in StockApril 20, 2026 | marketbeat.comOncocyte (NASDAQ:IMDX) Major Shareholder Purchases $352,096.65 in StockApril 20, 2026 | marketbeat.comReal-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure AssayApril 14, 2026 | globenewswire.comInsight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comIMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 ResultsMarch 26, 2026 | globenewswire.comiMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare ConferenceMarch 20, 2026 | globenewswire.comSecond Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model ScoreMarch 13, 2026 | globenewswire.comInsight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA SubmissionMarch 3, 2026 | globenewswire.comBroadwood Partners, L.P. Acquires 521,739 Shares of Oncocyte (NASDAQ:IMDX) StockFebruary 13, 2026 | insidertrades.comiMDx Announces $26.0 Million Registered Direct OfferingFebruary 11, 2026 | globenewswire.comIMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant MonitoringJanuary 13, 2026 | globenewswire.comiMDx Announces “JPM Week” and “BTIG Snowbird” Conference ParticipationJanuary 7, 2026 | globenewswire.comiMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay LaunchJanuary 6, 2026 | globenewswire.comiMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears CompletionJanuary 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVO, CNTB, ACOG, and IMDX Company DescriptionsAlpha Cognition NASDAQ:ACOG$6.10 +0.01 (+0.16%) Closing price 03:59 PM EasternExtended Trading$6.16 +0.06 (+0.90%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Connect Biopharma NASDAQ:CNTB$2.36 +0.03 (+1.29%) Closing price 04:00 PM EasternExtended Trading$2.37 +0.01 (+0.21%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.CervoMed NASDAQ:CRVO$3.95 +0.15 (+3.95%) Closing price 04:00 PM EasternExtended Trading$3.98 +0.03 (+0.76%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Oncocyte NASDAQ:IMDX$5.01 +0.05 (+1.01%) Closing price 04:00 PM EasternExtended Trading$4.89 -0.12 (-2.38%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
